Tengion, Inc. was a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. Its primary objective was the discovery, development, manufacturing, and commercialization of advanced cellular therapeutic products, often termed "neo-organs." These innovations, comprising living cells sometimes combined with synthetic or natural supporting materials, were intended for implantation or injection into the body to integrate, regenerate, or substitute for compromised tissues or organs. The company's product pipeline included two significant experimental therapies. Neo-Kidney Augment was designed to improve kidney function in patients suffering from advanced chronic kidney disease, with the goal of preventing or delaying the need for dialysis. The other, Neo-Urinary Conduit, was in Phase I clinical trials and aimed to provide an alternative to using intestinal tissue for urinary diversion following bladder removal surgery in bladder cancer patients who required a non-continent urinary solution. Tengion also held intellectual property rights pertaining to tissue engineering technology, acquired through a licensing agreement with Children's Medical Center Corporation (CMCC). However, the company's operations concluded when it voluntarily filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware on December 29, 2014.
—
Tengion, Inc. was a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. Its primary objective was the discovery, development, manufacturing, and commercialization of advanced cellular therapeutic products, often termed "neo-organs." These innovations, comprising living cells sometimes combined with synthetic or natural supporting materials, were intended for implantation or injection into the body to integrate, regenerate, or substitute for compromised tissues or organs. The company's product pipeline included two significant experimental therapies. Neo-Kidney Augment was designed to improve kidney function in patients suffering from advanced chronic kidney disease, with the goal of preventing or delaying the need for dialysis. The other, Neo-Urinary Conduit, was in Phase I clinical trials and aimed to provide an alternative to using intestinal tissue for urinary diversion following bladder removal surgery in bladder cancer patients who required a non-continent urinary solution. Tengion also held intellectual property rights pertaining to tissue engineering technology, acquired through a licensing agreement with Children's Medical Center Corporation (CMCC). However, the company's operations concluded when it voluntarily filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware on December 29, 2014.
—
Daily adjusted close
Tengion, Inc. was a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. Its primary objective was the discovery, development, manufacturing, and commercialization of advanced cellular therapeutic products, often termed "neo-organs." These innovations, comprising living cells sometimes combined with synthetic or natural supporting materials, were intended for implantation or injection into the body to integrate, regenerate, or substitute for compromised tissues or organs. The company's product pipeline included two significant experimental therapies. Neo-Kidney Augment was designed to improve kidney function in patients suffering from advanced chronic kidney disease, with the goal of preventing or delaying the need for dialysis. The other, Neo-Urinary Conduit, was in Phase I clinical trials and aimed to provide an alternative to using intestinal tissue for urinary diversion following bladder removal surgery in bladder cancer patients who required a non-continent urinary solution. Tengion also held intellectual property rights pertaining to tissue engineering technology, acquired through a licensing agreement with Children's Medical Center Corporation (CMCC). However, the company's operations concluded when it voluntarily filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware on December 29, 2014.